Search
Results
showing 1-10 of 1010
The Future of the HIV Response: Sustaining Progress in an era of Political Uncertainty and Scientific Opportunity
July 2026
Significant progress has been made in expanding access to HIV treatment and prevention, but major gaps in coverage and equity were further exacerbated and destabilized by changes in US government support in January 2025. This commentary by AVAC’s Executive Director Mitchell Warren examines the implications of this divergence and argues that the future of the HIV response depends less on new biomedical discoveries than on the capacity to deliver existing and emerging options sustainably and with speed, scale and equity.
The HIV Prevention Pipeline
July 2026
This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.
AVAC Infographics for AIDS 2026
July 2026
For those presenting at AIDS 2026, AVAC’s latest infographics on the research and development pipeline, prevention options, and the impact of US funding cuts can be accessed here. We hope these are useful for presentations and discussions at the conference and beyond.
HIV Vaccine Clinical Trials Pipeline
July 2026
This graphic summarizes the state of HIV vaccine research, detailing the different immunological approaches in clinical trials, the specific candidates being studied, and the collaborative networks of funders and developers working toward an effective vaccine.
AVAC Comment Submission on the White House OMB Proposed Federal Financial Assistance Rule
July 2026
As an advocate for scientific integrity, public health and evidence-based policymaking, AVAC strongly opposes the White House Office of Management and Budget’s proposed Regulation for Federal Financial Assistance. This document outlines AVAC’s key concerns with the proposal, which were submitted July 9, 2026.
HIV Cure Research Cohorts
July 2026
HIV cure research depends on cohorts of people living with HIV who volunteer to participate in studies over many years. These cohorts help researchers understand how HIV persists in the body, identify factors that may influence the success of cure strategies and evaluate promising interventions. This infographic highlights major HIV cure research cohorts around the world, demonstrating the global collaboration and long-term investment required to advance HIV cure science.
HIV Prevention Product Overview
July 2026
The graphic provides an overview of PrEP products currently available and in late-stage clinical trials.
What Does It Take to Conduct HIV Cure Research?
July 2026
Progress towards an HIV cure depends on strengthening four critical systems: lab equipment, sustainable funding, policy & programs, and training.
ARV-Based and Multipurpose Prevention Technology R&D Pipeline
July 2026
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
Years Ahead in HIV Prevention Research: Time to Market
July 2026
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
showing 1-10 of 1010